Skip to main content

Table 1 Treatment-related adverse events

From: Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

 

Dose (mg/kg)

Grade 1, N (%)

Grade 2, N (%)

Nausea

4 and 8

2 (13.3)

0

Headache

4

1 (6.7)

0

Chills

8

1 (6.7)

0

Throat tightness

8

1 (6.7)

0

Decreased WBC

16

1 (6.7)

0

Fatigue

32

1 (6.7)

2 (13.3)

Constipation

32

1 (6.7)

0

Hypersomnia

32

0

2 (13.3)

Hypophosphatemia

32

0

2 (13.3)

  1. All adverse events at least possibly attributed to study drug are shown. There were no grade 3 or grade 4 treatment-related adverse events. Adverse event grade is according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0
  2. kg kilogram
  3. mg milligram
  4. WBC white blood cell
Back to article page